Finerenone May Protect Against Pneumonia and COVID-19
Finerenone, a mineralocorticoid receptor antagonist, may exert anti-inflammatory and anti-fibrotic effects, according to investigators.
Finerenone, a mineralocorticoid receptor antagonist, may exert anti-inflammatory and anti-fibrotic effects, according to investigators.
Researchers evaluate the lifetime cost-effectiveness of using SGLT2 inhibitors or GLP1 receptor agonists as first-line treatments for type 2 diabetes.
The multicenter, randomized, controlled GRADE study was designed to compare the effectiveness of 4 major FDA-approved medications.
Investigators conducted a meta-analysis of randomized controlled trials on the effect of SGLT-2 inhibitors on patients with HFpEF.
The 26-week ONWARDS 3 and 4 clinical trials evaluated the efficacy and safety of insulin icodec in adults with type 2 diabetes.
Sotagliflozin is an investigational dual sodium-glucose co-transporter types 1 and 2 (SGLT1, SGLT2) inhibitor.
Researchers assessed the relationship between fasting blood glucose levels and the risk of mortality in patients hospitalized with COVID-19.
The recalled product does not pertain to the branded interchangeable biosimilar, Semglee (insulin glargine-yfgn).
Teplizumab is an investigational anti-CD3 monoclonal antibody that has been shown to preserve beta cell function, reducing the need for exogenous insulin.
The sBLA is supported by data from the phase 3 PANORAMA trial and the NIH-sponsored Protocol W trial.